Augustine Bourne is Vice President, Business Development at Sapience Therapeutics. Augustine has over 15 years of experience in the biotech and financial services industries.
Most recently, he led business development and corporate strategy activities at Mirati Therapeutics (acquired by Bristol Myers Squibb for up to $5.8B). Prior to Mirati, he served in roles of increasing responsibility at Regeneron, where he provided strategy and business development leadership in support of Regeneron’s oncology and hematology pipelines. Augustine began his career as a lawyer in the London and New York offices of Weil, Gotshal & Manges, where he advised the firm’s clients on strategic transactions and securities offerings.
Augustine received his MBiochem from the University of Oxford, GDL/LPC from BPP Law School and MBA from Columbia Business School.